Without RCT data on semaglutide for the management of BAD, it is difficult to evaluate its safety and efficacy compared with other BAD therapeutics, but the abovementioned case underscores that newer, longer-acting, and more potent GLP-1RAs not necessarily provide better treatment results in BAD as compared with older, shorter-acting, and less potent GLP-1RAs such as liraglutide
Glukagon-lik peptid-1, GLP-1, och glukosberoende insulinotropisk polypeptid, GIP, r tv peptidhormoner som fristts i tarmkanalen vid fdointag och spelar en avgrande roll fr aptitreglering, nringsintag, magtmningshastighet och gastrointestinal motilitet
Phentermine vs
If the patient stops the medication, weight gain may occur, causing frustration and disappointment and a return of certain obesity-related health problems